Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis
Status:
Completed
Trial end date:
2017-09-27
Target enrollment:
Participant gender:
Summary
This is a phase III trial to determine whether adjunctive sertraline will lead to improved
survival 18-week survival.
There was an initial phase I/II unmasked dose finding pharmacokinetic study of CSF
concentrations in 172 persons conducted from August 2013 to August 2014. See NCT03002012.
Phase:
Phase 3
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute
Collaborators:
Ifakara Health Institute Infectious Disease Institute, Kampala, Uganda Makerere University Mbarara University of Science and Technology Medical Research Council National Institute of Neurological Disorders and Stroke (NINDS) Wellcome Trust